Mostrar el registro sencillo del documento

dc.creatorJamerson, Brenda D.
dc.creatorHaryadi, T. Ho
dc.date.accessioned2020-07-16T02:03:24Z
dc.date.available2020-07-16T02:03:24Z
dc.date.created2020-11
dc.identifier.issn0306-9877spa
dc.identifier.otherhttps://www.sciencedirect.com/science/article/pii/S0306987720309488?via%3Dihubspa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/10618
dc.format.extent2 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.publisherScience Directeng
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectIbuprofenospa
dc.titleThe use of ibuprofen to treat fever in COVID-19: A possible indirect association with worse outcome?spa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.subject.keywordIbuprofenspa
dc.identifier.doihttps://doi.org/10.1016/j.mehy.2020.109880spa
dc.description.abstractenglishFever has been reported as a common symptom occurring in COVID-19 illness. Over the counter antipyretics such as ibuprofen and acetaminophen are often taken by individuals to reduce the discomfort of fever. Recently, the safety of ibuprofen in COVID-19 patients has been questioned due to anecdotal reports of worsening symptoms in previously healthy young adults. Studies show that ibuprofen demonstrates superior efficacy in fever reduction compared to acetaminophen. As fever may have benefit in shortening the duration of viral illness, it is plausible to hypothesize that the antipyretic efficacy of ibuprofen may be hindering the benefits of a fever response when taken during the early stages of COVID-19 illness.spa


Archivos en el documento

Thumbnail

Este documento aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del documento